Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2023 Sep 1;51(9):e185-e186.
doi: 10.1097/CCM.0000000000005934. Epub 2023 Aug 17.

Sodium-Glucose Cotransporter 2 Inhibitors Decrease the Risk of Acute, Severe Illness: Has the Time Come to Administer Them in the Acute Setting?

Dimitrios Patoulias  1   2
Affiliations
Comment

Sodium-Glucose Cotransporter 2 Inhibitors Decrease the Risk of Acute, Severe Illness: Has the Time Come to Administer Them in the Acute Setting?

Dimitrios Patoulias. Crit Care Med. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Dr. Patoulias has disclosed that he does not have any potential conflicts of interest.

Comment in

  • The authors reply.
    Ng PY, Ng AK, Ip A, Yiu KH. Ng PY, et al. Crit Care Med. 2023 Sep 1;51(9):e186-e187. doi: 10.1097/CCM.0000000000005946. Epub 2023 Aug 17. Crit Care Med. 2023. PMID: 37589525 No abstract available.

Comment on

References

    1. Ng PY, Ng AK, Ip A, et al.: Risk of ICU admission and related mortality in patients with sodium-glucose cotransporter 2 inhibitors and dipeptidyl peptidase-4 inhibitors: A territory-wide retrospective cohort study. Crit Care Med. 2023; 51:1074–1085
    1. Wu MZ, Chandramouli C, Wong PF, et al.: Risk of sepsis and pneumonia in patients initiated on SGLT2 inhibitors and DPP-4 inhibitors. Diabetes Metab. 2022; 48:101367
    1. Voors AA, Angermann CE, Teerlink JR, et al.: The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: A multinational randomized trial. Nat Med. 2022; 28:568–574
    1. Kosiborod MN, Esterline R, Furtado RHM, et al.: Dapagliflozin in patients with cardiometabolic risk factors hospitalised with COVID-19 (DARE-19): A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Diabetes Endocrinol. 2021; 9:586–594
    1. Mazer CD, Arnaout A, Connelly KA, et al.: Sodium-glucose cotransporter 2 inhibitors and type 2 diabetes: Clinical pearls for in-hospital initiation, in-hospital management, and postdischarge. Curr Opin Cardiol. 2020; 35:178–186

MeSH terms

Substances

LinkOut - more resources